• Immuron enters exclusive distribution agreement for ProIBS® in Australia and New Zealand
• ProIBS® contains AVH200® derived from Aloe barbadensis plant to support intestinal mucosal barrier
• Usability study showed 94% of 1,003 users found ProIBS® helpful, 91% experienced improved daily life

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, has entered into an exclusive distribution agreement with Calmino group AB to launch ProIBS®, a certified medical device for the treatment of irritable bowel syndrome (IBS) symptoms, in Australia and New Zealand. ProIBS® contains AVH200®, derived from the Aloe barbadensis plant, which has gel-forming components that support the intestinal mucosal barrier. IBS is a common condition affecting around 30% of people, particularly females, with symptoms including abdominal pain, bloating, and alternating diarrhea and constipation. According to market data, the IBS treatment market in Australia is estimated to generate revenue of around AU$221.14 million in 2025, with a projected annual growth rate of 3.28%. The agreement is for a 5-year term with an option to extend for an additional 5 years, and Immuron will fund the collaboration from existing budgets and resources. A usability study among 1,003 users found that 94% found ProIBS® helpful, 91% experienced an improvement in daily life, and 98% would recommend the product to someone else.

Immuron sees a great opportunity to expand its digestive health portfolio by providing pharmacists a proven premium efficacy product that delivers unique benefits to their customers with ProIBS®. The company is looking forward to offering a solution that truly improves the liveability of people affected by IBS.